Core Insights - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2025, indicating a mixed performance with Q4 revenue growth but an overall decline for the year [1][5]. Financial Performance - Q4 2025 total revenue is expected to be between $20.3 million and $20.4 million, reflecting a 7% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2025 total revenue is projected to be between $77.3 million and $77.4 million, representing a 3% decrease at the estimated midpoint compared to the previous year [3]. - Cash and cash equivalents as of December 31, 2025, were approximately $92 million, slightly down from $92.4 million as of September 30, 2025 [4]. Business Developments - The company achieved significant milestones in Dry Eye reimbursement and continued momentum in Surgical Glaucoma, with Dry Eye revenues expected to increase by approximately 130% compared to the prior year [5][7]. - Surgical Glaucoma revenues are anticipated to remain flat at the estimated midpoint compared to the previous year, with expected revenues between $75.6 million and $75.7 million [7]. - The company reported cash used in Q4 totaled approximately $0.4 million, with a total of approximately $28 million used during the year, indicating operational discipline [7]. Future Outlook - The company expressed confidence in its growth outlook and operational discipline, aiming for cash flow breakeven without requiring additional equity capital [5]. - Complete financial results for Q4 and full year 2025 are expected to be announced in March 2026 [5].

Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at the Stifel 2025 Healthcare Conference on November 11, 2025, and at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 [2] Company Overview - Sight Sciences develops and commercializes minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The company's key products include the OMNI Surgical System and OMNI Edge Surgical System, which are implant-free technologies for glaucoma surgery, and the TearCare System for treating evaporative dry eye disease [3] Product Details - The OMNI Surgical System is CE Marked for reducing intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION Surgical System is a bladeless device for excising trabecular meshwork in ophthalmic procedures [3] - The TearCare System is 510(k) cleared for localized heat therapy to clear gland obstructions in patients with meibomian gland disease [3]

Core Insights - The 24-month results from Stage 3 of the SAHARA trial demonstrate significant and sustained improvements in signs and symptoms of dry eye disease for participants treated with the TearCare System [1][3][5] - A majority of participants (66%) required no additional treatment after initial TearCare treatments, indicating the durability of the treatment effect [2][7] Study Results - All mean signs and symptoms remained statistically significantly better than the study baseline at all measured time points up to 24 months [2][5] - Tear breakup time (TBUT) improved from a baseline of 4.41 seconds to a range of 6.29 to 7.13 seconds at Month 24, with p<.0001 indicating strong statistical significance [5] - Meibomian Gland Secretion Score (MGSS) showed sustained improvement from Month 6 (7.26) to Month 24 (means ranging from 17.68 to 18.95), also with p<.0001 [5] - Subjective symptoms assessed by Ocular Surface Disease Index (OSDI), symptom assessment in dry eye (SANDE), and eye dryness score (EDS) remained significantly better than baseline values at all follow-up time points [5][6] Treatment Efficacy - The study confirmed that just two TearCare treatments within five months can lead to meaningful, lasting improvements for up to two years [3][9] - The median time for first retreatment was 7 months, with a 6-month retreatment-free survival probability of 92% [7]

Core Viewpoint - Sight Sciences, Inc. has launched the OMNI Edge Surgical System, enhancing its OMNI product family with advanced features for minimally invasive glaucoma surgery (MIGS) [1][2][5] Product Features - OMNI Edge incorporates TruSync™ technology, which synchronizes viscoelastic delivery with the surgeon's control, allowing for consistent deployment along Schlemm's canal [2][13] - The system features an expanded viscoelastic capacity of 21 µL, nearly double the previous 11 µL capacity of the OMNI Surgical System, while maintaining safety and usability [2][13] - OMNI Edge is designed to treat all three areas of resistance in the aqueous outflow system, making it versatile for various stages of primary open-angle glaucoma (POAG) [2][7] Clinical Insights - Early clinical use of OMNI Edge has been positively received, with enhancements in ergonomics and predictability noted by practitioners [3] - The OMNI procedure has demonstrated safety, effectiveness, and durability in over 300,000 procedures, establishing its leadership in canal-based MIGS [4] Market Position - The introduction of OMNI Edge allows surgeons to choose between OMNI and OMNI Edge technologies, catering to diverse surgical preferences and patient needs [5] - OMNI Edge is currently available only in the United States, indicating a focused market strategy [5] Company Commitment - Sight Sciences emphasizes its dedication to innovation in glaucoma care through ongoing collaboration with the ophthalmic community [4]